Walgreen, Kroger, Safeway, SuperValu, and HEB have sued Pfizer and Ranbaxy, accusing the drug manufacturers of conspiring to delay generic versions of Lipitor (atorvastatin). Pfizer markets Lipitor and Ranbaxy manufactures the generic version.
The conspiracy allegedy called for a fraudulent patent, sham litigation, a pay-for-delay agreement, and agreements with pharmacy benefit managers requiring them to buy more Lipitor. The retailers claim that these actions kept Lipitor off the market 20 months past the expiration of the original patent.
Lipitor is used to lower cholesterol. It is the best-selling drug in pharmaceutical history.
Full content: Reuters
Related content: Federal Trade Commission Suffers Another Setback in Its Campaign to End Pharmaceutical Reverse-Settlement Agreements
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Google and South Carolina Clash Over State Records Demand
May 8, 2024 by
CPI
Telefonica Germany Teams Up with Amazon Web Services to Migrate 5G Customers
May 8, 2024 by
CPI
Federal Judge Grants $7.4 Million Settlement in Pork Price-Fixing Case
May 8, 2024 by
CPI
Wilson Sonsini Bolsters Antitrust and Competition Practice with Key Partner Returns
May 8, 2024 by
CPI
EU to Scrutinize Telecom Italia’s Network Sale to KKR
May 8, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI